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Objective. To determine if levels of endogenous
estrogen or estrogen metabolites are associated with an
increased risk of developing knee osteoarthritis (OA) in
women.
Methods. Serum estradiol (E2) and 2 urinary
estrogen metabolites (2-hydroxyestrone and 16-
hydroxyestrone) with radiographically defined preva-
lent and incident knee OA in 842 white and African
American women from the Southeast Michigan Arthri-
tis Cohort.
Results. The mean age and body mass index
(BMI) of women in the cohort were 42.3 years and 28.5
kg/m2, respectively. Women who developed radiograph-
ically defined knee OA had significantly greater odds of
having baseline endogenous early follicular phase estra-
diol concentrations in the lowest tertile (<47 pg/ml;
odds ratio [OR] 1.88, 95% confidence interval [95% CI]
1.07–3.51) compared with those with estradiol concen-
trations in the middle tertile [47–77 pg/ml]), after
adjustment for age, BMI, and other covariates. Women
who developed knee OA also had greater odds of having
baseline urinary concentrations of 2-hydroxyestrone in
the lowest tertile (OR 2.9, 95% CI 1.49–5.68) compared
with women with 2-hydroxyestrone concentrations in the
middle tertile), after adjustment for covariates. Women
who developed knee OA were more likely to have a ratio
of 16-hydroxyestrone to 2-hydroxyestrone in the high-
est tertile (>0.86; OR 1.86, 95% CI 1.01–3.44 compared
with women with ratios in the 0.54–0.86 range), after
adjustment for other covariates.
Conclusion. There were significant associations
of lower baseline serum estradiol and urinary 2-
hydroxyestrone with developing knee OA in middle-aged
women.
Osteoarthritis (OA) of the knee is characterized
by progressive degeneration of articular cartilage along
with structural changes in the underlying bone, including
development of marginal growths, osteophytes, and in-
creased thickness of the bony envelope (1–3). Sex dif-
ferences in OA prevalence suggest that sex hormones or
alterations in reproductive hormone concentrations that
occur with menopause contribute to arthritis pathology
(4–6). Because OA is more prevalent in women,
emerges at ages 40–50 years, and has pathobiologic
underpinnings related to synthesis, inflammation, and
repair, it has been suggested that reproductive hormones
have a role in the natural history of developing OA. Sex
hormones can impact tissues associated with knee OA
through direct cellular and molecular action on the
synoviocytes, chondrocytes, and bone cells, as reflected
in processes such as collagen synthesis, maintenance of
bone stiffness, or modulation of excess expression of
cytokines (4,5).
Circulating estradiol (E2), the primary estrogen
in premenopausal and early perimenopausal women,
declines with menopause. Further, products of estradiol
catabolism, including 2-hydroxyestrone and 16-
hydroxyestrone, may also have important roles with
respect to arthritis (7). Estradiol is preferentially con-
verted to estrone by the 17-hydroxysteroid dehydro-
genase enzyme, after which there is subsequent metab-
olism by the cytochrome P450 enzymes (8) (Figure 1).
The 16-hydroxyestrone acts as an estrogen agonist in
some model systems, while 2-hydroxyestrone may have
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weak estrogenic activity (9–11). The 16-hydroxyestrone
can bind covalently and noncovalently to the estro-
gen receptor (ER), although with less affinity than
estradiol (12). However, since 16-hydroxyestrone has
a low affinity for serum sex hormone binding glob-
ulin, it is more available for estrogen-sensitive target
tissues (12). Although 2-hydroxyestrogens have re-
duced binding affinity for the ER (13,14), they appear
to have additional important properties, including
participation in oxidation/reduction actions (15) and
modulating the physiologic effects of arachidonic acid
metabolism and prostaglandins (16). Higher ratios of
16-hydroxyestrone to 2-hydroxyestrone have been as-
sociated with several diseases, including reproductive
cancers, systemic lupus erythematosus (SLE), liver cir-
rhosis, and osteoporosis (12,17–20).
The goal of this study was to evaluate the asso-
ciations of serum estradiol, urinary 2-hydroxyestrone,
and urinary 16-hydroxyestrone as risk factors for knee
OA in women, while controlling for effects of other
known risk factors for OA.
PATIENTS AND METHODS
Sampling and study population. Premenopausal and
perimenopausal women from 2 longitudinal studies were eval-
uated using a protocol common to both studies (21). This study
includes data on 458 women from the Michigan Bone Health
Study (MBHS) and 384 women from the Study of Women’s
Health Across the Nation (SWAN), who had radiographs of
both knees as well as urine and serum specimens available for
analyses of hormones. Collectively, these study groups are
known as the Southeast Michigan Arthritis Cohort, and the
cohort has been described previously (21).
SWAN is a population-based longitudinal study of the
menopausal transition. In 1996, 543 eligible women (325
African American and 218 white) who met the age (42–52
years), menstrual status (menstrual bleeding within the previ-
ous 3 months and had not received hormone replacement
therapy [HRT]), and ethnicity criteria specified by the study
protocol were enrolled. In 1996–1997, a site-specific study of
physical functioning, including radiographic measures of OA,
was implemented in the SWAN population. Cumulatively, loss
to followup of living enrollees has been 20%.
MBHS, begun in 1992, is a population-based longitu-
dinal study of musculoskeletal disease development in pre-
menopausal and perimenopausal white women. The 664-
woman sample was identified from the family records of
participants in the historic Tecumseh Community Health
Study (TCHS) and a 1992 Tecumseh, Michigan, community
census. From the TCHS, 80% of the female offspring who
were 24–44 years old in 1992 were recruited. Additionally,
90% of the eligible women from the community census who
were not part of the TCHS were recruited. Loss to followup
was 15% over a 10-year time period. Measures of physical
functioning, including radiographically defined knee and hand
OA, were obtained in the same time frame as in the Michigan
SWAN population (5,21).
Approval for this study was obtained from the Univer-
sity of Michigan Institutional Review Board.
Scoring system. Interviews addressing pain, health
status (including medications), and lifestyle, as well as phle-
botomy were completed annually. Radiographs of the knee
were obtained at the time of annual assessment, but 3 years
apart, and were used to define 2 outcomes, the prevalence and
the incidence of radiographically defined knee OA.
Anteroposterior radiographs of both knees were ob-
tained, using General Electric (Milwaukee, WI) radiographic
equipment and Kodak film (Eastman Kodak, Rochester, NY).
Standard radiographic techniques were used. Radiographs of
weight-bearing knee joints were evaluated by 2 readers (MH,
DAJ) independently, using the Kellgren/Lawrence (K/L) scor-
ing system (22). This scoring system is highly sensitive to the
presence of osteophytes and is considered appropriate to
identify the initial stages of OA, which commonly develops
during middle age. Using this system, a score of 0–4 was
assigned to the joints based on the degree of osteophyte
formation, joint space narrowing, sclerosis, and joint deform-
ity. According to the K/L scale, 0  normal, 1  doubtful OA,
2  minimal OA, 3  moderate OA, and 4  severe OA.
Consistency of grading between evaluators was determined
and joint grading was standardized. If the 2 readers did not
agree on a grade, a consensus approach including a third
reader (MRS) was used. A set of “drift” films was also included
to help ensure that there had been no change over time in
assignment of a given K/L score to a given set of findings.
Women were classified as having prevalent knee OA if they
had a radiograph with a K/L score 2; women were classified
as having incident knee OA if they were free of disease at
baseline, but knee OA was identified in subsequent radio-
graphs. Of the 3,768 knee radiographs evaluated according to
this protocol, the readers concurred on the K/L score in 3,399
(90%); 369 radiographs had to be reread by consensus.
Exposure measures. Blood was drawn during the an-
nual study visits, 2–7 days following menses (early follicular
phase of the menstrual cycle), and after a 12-hour fast. The
blood was refrigerated for up to an hour and then centrifuged
to provide serum that was then frozen at 80°C until assay.
Figure 1. Pathway of estrogen metabolism including estradiol, es-
trone, and estrogen metabolites. 17 HSD  17-hydroxysteroid dehy-
drogenase.
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For those women with no menstrual bleeding or who were
receiving HRT, blood was drawn on the anniversary of the
baseline examination.
Serum estradiol concentrations were measured using a
modified, offline automated chemiluminescence system E2-6
immunoassay (ACS:180; Bayer Diagnostics, Tarrytown, NY).
Inter- and intraassay coefficients of variation (CVs) were
10.6% and 6.4%, respectively, over the assay range. The estrogen
metabolites 2-hydroxyestrone and 16-hydroxyestrone were
measured from urine that had been obtained in the year prior
to radiographic diagnosis of knee OA. The estrogen metabo-
lites were measured by enzyme-linked immunosorbent assay
(Estramet; Immuna Care, Blue Bell, PA) from samples col-
lected prior to radiographic assessment and were run in
triplicate (23). Interassay CVs were 13.4% (3.8 ng/ml) and
11.3% (6.3 ng/ml). The intraassay CV was 5.5% over the
working assay range (1.1–12.1 ng/ml).
Body mass index (BMI) was calculated as kg/m2, with
weight measured using a balance beam scale and height
measured using a stadiometer. Participants were classified as
current smokers, those who had ever smoked, or those who
had never smoked. A history of knee injury was determined
using an arthritis questionnaire to identify pain and clinical
characteristics. It was administered at the same time at which
radiographs were obtained. Women were classified as pre-
menopausal, receiving HRT (including oral contraceptives),
menopausal (naturally, surgically, or chemotherapy-induced),
or having undergone a hysterectomy, with ovaries intact and no
hormone use. Of the 107 women who had ever taken repro-
ductive hormones, 65 were premenopausal, with the following
hormone use patterns: 52 women (80%) took oral contracep-
tives, 7 women (11%) took a combination of conjugated
estrogen and progesterone, 3 women (5%) took progesterone
only, and 3 women (5%) took conjugated estrogens only. Of
the 42 naturally or surgically postmenopausal women who took
reproductive hormones, 37 women (88%) took conjugated
estrogens, 3 women (7%) took a combination of conjugated
estrogen and progesterone, and 2 women (5%) took oral
contraceptives with estrogen.
Statistical analysis. All univariate, bivariate, and mul-
tivariate analyses were performed using SAS software, version
8.0 (SAS Institute, Cary, NC). The mean, median, standard
deviation, and minimum and maximum values were calculated
for all continuous variables, including the 2-hydroxyestrone
and 16-hydroxyestrone concentrations (and their ratio), es-
tradiol, BMI, and baseline age. All continuous variables were
evaluated for consistency with a normal distribution and were
log-transformed, as appropriate, to satisfy the normality as-
sumption in parametric testing. Frequencies and percentages
were calculated for all categorical variables, including preva-
lence and incidence of knee OA, smoking, reproductive status,
and history of knee injury.
Multivariate logistic regression models were used to
examine the associations between prevalence and incidence of
knee OA and estrogen metabolites and estradiol, adjusting for
BMI, age, smoking history, history of knee injury, day of blood
draw, and menstrual status. BMI and age were held at their
baseline levels for all logistic models, and were assessed for
interaction with estradiol or the metabolites with respect to
prevalent or incident knee OA. No significant interactions
were found, and the final logistic models included no interac-
tion terms. Day of blood draw was initially included in each
logistic model, but was excluded from final models because it
was not significant, and the odds of prevalent or incident knee
OA according to estradiol or estrogen metabolite concentra-
tions were unaffected by its inclusion. Final models also did not
include menstrual status, because at the followup assessment,
only 7 of 58 naturally or surgically postmenopausal women
(12%) presented with prevalent knee OA. Among premeno-
pausal and early perimenopausal women, however, the odds of
prevalent and incident knee OA according to estradiol and
estrogen metabolite concentrations were consistent in magni-
tude and significance with those of the larger study population.
C statistics were used to characterize the goodness-of-
fit of models. Type I error was assessed based on 2-sided tests.
P values less than 0.05 were considered significant.
RESULTS
The baseline prevalence of knee OA in this
sample was 11%, while the annual incidence was 3.2%.
The mean  SD age at baseline in the study sample was
42  0.2 years (range 26–54 years). The mean  SD
BMI was 27.9  0.1 kg/m2. More than three-fourths of
the women were premenopausal at the baseline exami-
nation.
The mean  SD adjusted serum E2 concentration
was 62  43 pg/ml, as shown in Table 1. While the mean
serum E2 value was 15% lower in women with incident
knee OA, this difference was not statistically significant.
The mean  SD 2-hydroxyestrone and 16-
hydroxyestrone concentrations were 11.2  8.6 ng/ml
and 7.8  5.8 ng/ml, respectively. As shown in Table 1,
the 2-hydroxyestrone and 16-hydroxyestrone values
were 15% lower in those women with incident knee
OA; these differences were statistically significant.
Women with prevalent or incident knee OA also had
significantly larger ratios of 16-hydroxyestrone to
2-hydroxyestrone (mean  SD 0.76  0.47 for prevalent
knee OA and 0.83  0.51 for incident knee OA),
compared with women without knee OA (0.68  0.51).
Associations with incident knee OA. As shown in
Table 2, women who developed knee OA over the 3-year
period had greater odds of having baseline endogenous
estradiol concentrations in the lowest tertile (47 pg/ml;
OR 1.88, 95% CI 1.07–3.51 compared with estra-
diol concentrations in the middle tertile [47–77 pg/ml]),
after adjustment for covariates including age and re-
productive status. Women who developed knee OA
also had greater odds of having baseline urinary
2-hydroxyestrone concentrations in the lowest tertile
(OR 2.91, 95% CI 1.49–5.68) compared with women
ESTROGENS AND THE RISK OF KNEE OA 2483
with 2-hydroxyestrone concentrations in the middle ter-
tile. As a result, women who developed knee OA were
also more likely to have a 16-hydroxyestrone to
2-hydroxyestrone ratio in the highest tertile (0.86; OR
1.86, 95% CI 1.01–3.44 compared with women with
ratios in the 0.54–0.86 range), even after adjustment for
Table 1. Hormone concentrations classified according to knee OA, smoking, and reproductive status*
Estradiol,
mean  SD pg/ml
2-hydroxyestrone,
mean  SD ng/ml
16-hydroxyestrone,




Overall 62  43 11.2  8.6 7.8  5.8 0.70  0.29
Knee OA
Prevalence (baseline)
No knee OA (n  745 [89]) 62  44 11.3  8.2 7.8  5.5 0.69  0.27
Knee OA (n  89 [11]) 69  48 10.2  8.5 7.7  4.7 0.76  0.47†
Incidence (3-year)
No knee OA (n  656 [90]) 63  43 11.8  10.2 8.0  5.1 0.68  0.51
Knee OA (n  71 [10]) 54  38 8.3  6.7† 6.8  4.2† 0.83  0.51†
Smoking at baseline
Current (n  170 [20]) 61  42 14.9  13‡ 9.3  6.5‡ 0.62  0.39‡
Past/never (n  661 [80]) 63  44 10.4  7.7 7.5  5.1 0.72  0.51
Baseline reproductive status
Premenopausal (n  695 [83.5]) 63  42§ 11.0  10.5 7.6  5.3 0.69  0.53
Hormone therapy use (n  107 [13]) 54  38§ 11.9  10.3 8.7  6.2 0.73  0.41
Postmenopausal (n  4 [0.5]) 28  19§ 8.3  7.4 6.3  4.2 0.84  0.52
Hysterectomy (n  24 [3]) 103  71§ 16.5  13.4 10.9  6.9¶ 0.67  0.39
* A total of 842 patients were studied; however, for each category shown, data were not available on all patients (n values are the number for whom
data were available; values in brackets are percents). Age- and body mass index–adjusted pairwise comparisons are based on differences between
group least squares means  SEM. OA  osteoarthritis.
† P  0.05 versus no OA.
‡ P  0.05 versus past/never smokers.
§ Value for each status significantly different (P  0.05) from all others.
¶ P  0.05 versus premenopause and postmenopause.
Table 2. Odds ratios and 95% confidence intervals for having levels of estradiol and the estrogen
metabolites 2-hydroxyestrone and 16-hydroxyestrone in the lowest or highest tertile, in women with








33rd percentile (47 pg/ml) 1.20 (0.75–1.91) 1.88 (1.07–3.51)†
33rd–66th percentile (47–77 pg/ml) Referent Referent
66th percentile (78 pg/ml) 1.06 (0.66–1.71) 1.04 (0.52–2.09)
c statistic 0.74 0.74
log2-hydroxyestrone
33rd percentile (7.5 ng/ml) 1.62 (1.03–2.55) 2.91 (1.49–5.68)
33rd–66th percentile (7.6–15.3 ng/ml) Referent Referent
66th percentile (15.4 ng/ml) 0.62 (0.37–1.03) 1.06 (0.49–2.29)
c statistic 0.76 0.75
log16-hydroxyestrone
33rd percentile (6.1 ng/ml) 1.37 (0.86–2.18) 1.36 (0.74–2.51)
33rd–66th percentile (6.2–9.5 ng/ml) Referent Referent
66th percentile (9.6 ng/ml) 0.85 (0.52–1.41) 0.87 (0.44–1.71)
c statistic 0.75 0.72
log16-hydroxyestrone: 2-hydroxyestrone ratio
33rd percentile (0.53) 0.73 (0.45–1.21) 0.87 (0.44–1.73)
33rd–66th percentile (0.54–0.86) Referent Referent
66th percentile (0.87) 1.65 (1.05–2.61) 1.86 (1.01–3.44)
c statistic 0.75 0.73
* All models were adjusted for age, body mass index, reproductive status, race/ethnicity, and history of
knee injury. OA  osteoarthritis; OR  odds ratio; 95% CI  95% confidence interval.
† P  0.05.
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other covariates. Similar patterns were seen with preva-
lent knee OA and are also shown in Table 2.
Correlations of hormone levels with BMI. Estra-
diol concentrations were not highly correlated with
concentrations of the estrogen metabolites, although
levels of the metabolites were highly and positively
correlated with each other (r  0.67) (Table 3). In this
sample, BMI was negatively correlated with
2-hydroxyestrone, i.e., as BMI increased, there was less
2-hydroxyestrone. Similarly, as age increased, there was
less 16-hydroxyestrone.
DISCUSSION
There has been an ongoing debate as to whether
hormone levels contribute to the pathogenesis of OA
and/or serve as a biomarker of risk for the development
of OA. In humans, this debate has been largely focused
on HRT, under the assumption that HRT was correcting
an estradiol deficiency resulting from natural or surgical
menopause. It is now increasingly recognized that using
HRT as a model for the impact of circulating endoge-
nous estradiol levels in abnormal conditions is flawed
because its users constitute a select and healthier sub-
group of the population of women. There have been
surprisingly few studies that have actually examined
hormone concentrations, particularly in relation to
newly developing OA among women in their 50s and
60s. There are no studies of other estrogens that have
biologic activities, including the 2-hydroxyestrone and
16-hydroxyestrone metabolites. We found lower serum
estradiol concentrations as well as lower amounts of
2-hydroxyestrone in women who subsequently devel-
oped knee OA. This, in turn, led to a higher ratio of
2-hydroxyestrone to 16-hydroxyestrone associated with
developing incident knee OA, even after adjusting for
age, injury, and BMI, characteristics which have been
previously identified in many studies as risk factors (21).
Selected work with animal models provides sup-
port for the increased odds of developing OA with lower
estradiol concentrations. It has long been reported that,
in tissue culture systems, estrogen stimulated collagen
synthesis in rat uteri (24). In bovine aortic smooth
muscle cells, estrogen was associated with a shift in
procollagen subfractions from type I to type III (25).
Nasatzky and colleagues reported that in chondrocytes
(and depending upon the 17-estradiol concentration as
well as the animal model used), 17-estradiol inhibited
cell proliferation, stimulated RNA synthesis, and stimu-
lated 35SO4 incorporation as well as collagen production
(26,27). Work in baboons (28) and other animal models
(29–31) suggests the presence of estrogen receptors in
the chondroblasts and chondrocytes of laryngeal elastic
and hyaline cartilage and in the articular cartilage of the
mandibular condyle. Likewise, Tsai and Liu (29) have
reported the presence of estrogen receptors in the
cartilage of rabbit femoral condyles.
Our work demonstrates that lower levels of es-
trone metabolites, especially 2-hydroxyestrone, are also
related to the development of OA. CP450 enzymes
generate multiple hydroxylated products, via estrome, in
estradiol catabolism. These products are hormonally
inactive or less active water-soluble products, which are,
in turn, excreted in the urine or feces. The lower levels
of 2-hydroxyestrone may be related to lower levels of
estradiol; however, the correlation between estradiol
concentrations and 2-hydroxyestrone was modest (r 
0.27).
The action of higher 2-hydroxyestrone concentra-
tions in delaying the development of knee OA poten-
tially may be through the arachidonic acid pathway,
including the inhibition of leukotriene synthesis
and modulation of lipoxygenases. Rosenkrans and col-
leagues (32) proposed that the effects of estrogens on
prostaglandins are specifically mediated through the
catechol metabolites (2- and 4-hydroxyestrogens) rather
than estradiol (33). This was confirmed by Alanko et al
(34), who reported that while estradiol had no effect
on arachidonic acid metabolism, the catechol estrogens





Estradiol 0.27 (0.0001) 0.16 (0.0001) 0.18 (0.0001)
2-hydroxyestrone 0.67 (0.0001) 0.65 (0.0001)
16-hydroxyestrone 0.06 (NS)
Body mass index 0.13 (0.0002) 0.17 (0.0001) 0.05 (NS) 0.19 (0.0001)
Age 0.04 (NS) 0.02 (NS) 0.15 (0.0001) 0.11 (0.001)
* P values are shown in parentheses. NS  not significant.
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were much more potent inhibitors of leukotriene syn-
thesis than thromboxane and prostaglandin E2 synthesis.
Seeger et al (35) showed that estrogen metabolites
increased prostacyclin synthesis in endothelial tissues
at near-physiologic concentrations. Catechol estrogens
appear to modulate lipoxygenases in vivo. To inhibit
leukotriene synthesis, catechol estrogens may inhibit
5-lipoxygenase by reducing the catalytically active
ferric enzyme to the catalytically inactive ferrous forms
(36). The inhibition of cyclooxygenase may be due to the
capability of catechol estrogen to remove the interme-
diate radical that is essential to the cyclooxygenase
mechanism (37).
There are now a limited number of reports of
altered patterns of estrogen metabolism in both SLE and
rheumatoid arthritis (RA) (18,19), suggesting that these
alterations may be associated with symptoms (pain and
inflammation) rather than disease (structural) onset and
progression, as reflected in the catabolism of articular
cartilage and endochondral ossification. Weidler et al
(18) reported that 2-hydroxyestrone concentrations were
10 times lower in a mixed clinical sample of male and
female patients with RA and SLE as compared with
healthy controls. In our homogeneous population com-
posed primarily of women in their 40s and 50s, the
2-hydroxyestrone concentrations in those with knee OA
were significantly less than those in women without knee
OA. However, more detailed investigation is required to
establish if primary pathways are associated with symp-
toms, duration of symptoms, symptom severity, or with
response in cartilage and bone. When we accepted every
woman who reported pain without specification of the
underlying pathology, a characteristic that was reported
by more than one-quarter of enrollees, there was no
association with pain. Greater understanding of these
metabolic activities has implications for the selection of
bone resorption and pain medication used in OA, in
addition to the development of OA (20).
High BMI is a well-documented risk factor for
the development of knee OA in both men and women,
and the assumption has been largely that this risk is
generated by load bearing on the knee, ankle, and foot
joints (38). However, greater amounts of adipose tissue,
seen among women with higher BMI, may also contrib-
ute to the estrogenic environment and influence chon-
drocytes or bone cells. It is now well established that
androstenedione is a major precursor of estrone and
that the conversion from this androgen to estrogen is
undertaken by aromatase in adipose tissue (39). In
menopause, estrone is produced by the peripheral aro-
matization of the adrenal androstenedione in the adi-
pose tissue. In this sample, BMI was negatively corre-
lated with 2-hydroxyestrone, i.e., as BMI increased,
there was less 2-hydroxyestrone. This suggests that adi-
pose tissue might influence an important hormonal
element in the development of knee OA as well as
contribute to the more traditional loading mechanism.
We noted higher estradiol levels among women
who had undergone a hysterectomy (Table 1). It is
thought that these levels were related to our inability to
draw blood in the 2–7-day window of the early follicular
phase of the menstrual cycle.
This study has strengths and limitations. The
study examined hormone concentrations in women who
were approaching or in the menopausal transition in
relation to the development of knee OA. The hormones
were related to incident knee OA but not to prevalent
knee OA. We point out that this measurement of
hormones temporally preceded the identification of
knee OA. Potentially, concurrent measurement of hor-
mone levels in women with prevalent knee OA would
include measurements in women with knee OA that
developed as a result of trauma or other causes to a
point that it is recognizable on radiograph. The study
time frame may not fully capture the arthritis develop-
ment processes. The study also does not identify which
tissues (for example, synoviocytes, chondrocytes, and
bone cells) might be directly impacted by the lower
levels of estradiol or 2-hydroxyestrone. The study does
not identify whether the observed associations are the
response to a receptor-mediated process (as in the case
of lower estradiol concentrations), to a cytokine-based
response (as in the case of 2-hydroxyestrone), or, poten-
tially, to both mechanisms.
In summary, this report describes the strong
associations of lower circulating estradiol and
2-hydroxyestrone levels with more knee OA (both preva-
lence and incidence). If findings are confirmed, then this
helps motivate new areas of investigation for interven-
tion. If the mechanistic explanation for 2-hydroxyestrone
levels lies, at least in part, in arachidonic acid metabo-
lism associated with pain and inflammation rather than
receptor binding, then consideration of alternative life-
style and therapeutic pathways to influence these me-
tabolites becomes increasingly viable.
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